脳腫瘍治療薬市場：治療タイプ、適応症、流通チャネル別-2025-2030年の世界予測

脳腫瘍治療薬市場は、2023年に20億3,000万米ドルと評価され、2024年には21億8,000万米ドルに達すると予測され、CAGR 7.43％で成長し、2030年には33億5,000万米ドルに達すると予測されています。

脳腫瘍治療薬の市場範囲は、脳腫瘍に特化した治療薬の市場開拓、生産、流通を包含します。これらには、膠芽腫、星細胞腫、乏突起膠腫のようなさまざまなタイプの脳腫瘍の治療を目的とした化学療法、標的療法、免疫療法、支持療法薬が含まれます。このような薬剤の必要性は、脳腫瘍の発生率が増加していることに起因しており、血液脳関門を通過し、より少ない副作用で改善された有効性を提供できる革新的な治療法が必要とされています。これらの薬剤の用途は主に病院、診療所、専門的ながん治療センターであり、エンドユーザーは医療関係者と、オーダーメイドのがん治療計画を必要とする患者です。

市場の成長は、医療技術の進歩、研究資金の増加、がんの早期発見に対する意識の高まりといった主要因の影響を受けています。個別化医療と次世代シークエンシング技術の出現は、標的治療の開発に大きな機会を提供し、成長の可能性をもたらしています。現在、製薬企業と研究機関の協力により、革新的な創薬と臨床試験の扉が開かれつつあります。こうした機会を活用するための主な推奨事項には、腫瘍の遺伝的・分子的プロファイリングに焦点を当てた薬剤の研究開発への投資が含まれ、これにより、より正確なターゲティングと患者の転帰の改善が可能になります。

しかし、この市場は、高い開発・承認コスト、厳しい規制要件、血液脳関門を効果的に通過するための課題などの制約にも直面しています。また、一部の脳腫瘍は侵攻性が強いため、再発率が高く、従来の治療法に抵抗性を示すことが多いことも大きな課題です。技術革新が必要とされる分野には、腫瘍の血管系や微小環境を効果的に標的とする薬剤の開発や、脳への薬剤送達を強化するナノ粒子などの新規デリバリー・システムなどがあります。市場の性質は非常にダイナミックで競争が激しく、アンメットニーズを満たし、既存の市場の抑制要因を克服するためには、利害関係者による継続的な技術革新と適応が必要です。

市場力学：急速に進化する脳腫瘍治療薬市場の主要市場インサイトを公開

脳腫瘍治療薬市場は、需要と供給のダイナミックな相互作用によって変貌を遂げています。このような市場力学の進化を理解することで、企業は十分な情報に基づいた投資決定、戦略的決定の精緻化、そして新たなビジネスチャンスの獲得に備えることができます。これらの動向を包括的に把握することで、企業は政治的、地理的、技術的、社会的、経済的な領域にわたる様々なリスクを軽減することができ、また、消費者行動とそれが製造コストや購買動向に与える影響をより明確に理解することができます。

• 市場促進要因
  • 座りがちなライフスタイルに伴う脳腫瘍の有病率の増加
  • 神経障害を患う老年人口の急増
  • 治療の有効性に関する患者の意識の高まり
• 市場抑制要因
  • がんの成長を阻害する標的療法の使用
• 市場機会
  • 医薬品開発における政府や製薬会社の積極的な取り組み
  • 薬剤を運ぶためのナノ粒子の使用などの分野における力強い発展
• 市場の課題
  • これらの医薬品の承認における厳しい規制ガイドライン

ポーターの5つの力：脳腫瘍治療薬市場をナビゲートする戦略ツール

ポーターの5つの力フレームワークは、市場情勢の競合情勢を理解するための重要なツールです。ポーターのファイブフォース・フレームワークは、企業の競争力を評価し、戦略的機会を探るための明確な手法を提供します。このフレームワークは、企業が市場内の勢力図を評価し、新規事業の収益性を判断するのに役立ちます。これらの洞察により、企業は自社の強みを活かし、弱みに対処し、潜在的な課題を回避することができ、より強靭な市場でのポジショニングを確保することができます。

PESTLE分析：脳腫瘍治療薬市場における外部からの影響の把握

外部マクロ環境要因は、脳腫瘍治療薬市場の業績ダイナミクスを形成する上で極めて重要な役割を果たします。政治的、経済的、社会的、技術的、法的、環境的要因の分析は、これらの影響をナビゲートするために必要な情報を提供します。PESTLE要因を調査することで、企業は潜在的なリスクと機会をよりよく理解することができます。この分析により、企業は規制、消費者の嗜好、経済動向の変化を予測し、先を見越した積極的な意思決定を行う準備ができます。

市場シェア分析脳腫瘍治療薬市場における競合情勢の把握

脳腫瘍治療薬市場の詳細な市場シェア分析により、ベンダーの業績を包括的に評価することができます。企業は、収益、顧客ベース、成長率などの主要指標を比較することで、競争上のポジショニングを明らかにすることができます。この分析により、市場の集中、断片化、統合の動向が明らかになり、ベンダーは競争が激化する中で自社の地位を高める戦略的意思決定を行うために必要な知見を得ることができます。

FPNVポジショニング・マトリックス脳腫瘍治療薬市場におけるベンダーのパフォーマンス評価

FPNVポジショニングマトリックスは、脳腫瘍治療薬市場においてベンダーを評価するための重要なツールです。このマトリックスにより、ビジネス組織はベンダーのビジネス戦略と製品満足度に基づき評価することで、目標に沿った十分な情報に基づいた意思決定を行うことができます。4つの象限によってベンダーを明確かつ正確にセグメント化し、戦略目標に最適なパートナーやソリューションを特定することができます。

戦略分析と推奨脳腫瘍治療薬市場における成功への道筋を描く

脳腫瘍治療薬市場の戦略分析は、世界市場でのプレゼンス強化を目指す企業にとって不可欠です。主要なリソース、能力、業績指標を見直すことで、企業は成長機会を特定し、改善に取り組むことができます。このアプローチにより、競合情勢における課題を克服し、新たなビジネスチャンスを活かして長期的な成功を収めるための体制を整えることができます。

本レポートでは、主要な注目分野を網羅した市場の包括的な分析を提供しています：

1.市場の浸透度：現在の市場環境の詳細なレビュー、主要企業による広範なデータ、市場でのリーチと全体的な影響力の評価。

2.市場の開拓度：新興市場における成長機会を特定し、既存分野における拡大可能性を評価し、将来の成長に向けた戦略的ロードマップを提供します。

3.市場の多様化：最近の製品発売、未開拓の地域、業界の主要な進歩、市場を形成する戦略的投資を分析します。

4.競合の評価と情報：競合情勢を徹底的に分析し、市場シェア、事業戦略、製品ポートフォリオ、認証、規制当局の承認、特許動向、主要企業の技術進歩などを検証します。

5.製品開発およびイノベーション：将来の市場成長を促進すると期待される最先端技術、研究開発活動、製品イノベーションをハイライトしています。

また、利害関係者が十分な情報に基づいた意思決定を行う上で役立つ重要な質問にも回答しています：

1.現在の市場規模と今後の成長予測は？

2.最高の投資機会を提供する製品、セグメント、地域はどこか？

3.市場を形成する主な技術動向と規制の影響とは？

4.主要ベンダーの市場シェアと競合ポジションは？

5.ベンダーの市場参入・撤退戦略の原動力となる収益源と戦略的機会は何か？

目次

第1章 序文

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 市場の概要

第5章 市場洞察

• 市場力学
  • 促進要因
    • 座りがちな生活習慣による脳腫瘍の罹患率の増加
    • 神経疾患を患う高齢者人口の急増
    • 治療の可用性に関する患者の意識の高まり
  • 抑制要因
    • がんの増殖を阻止するための標的療法の使用
  • 機会
    • 政府と製薬会社による薬の開発に対する好意的な取り組み
    • 薬物を運ぶためのナノ粒子の使用などの分野での堅調な開発
  • 課題
    • これらの医薬品の承認に関する厳格な規制ガイドライン
• 市場セグメンテーション分析
• ポーターのファイブフォース分析
• PESTEL分析
  • 政治的
  • 経済
  • 社交
  • 技術的
  • 法律上
  • 環境

第6章 脳腫瘍治療薬市場治療の種類別

• 化学療法
• 免疫療法
• 標的療法

第7章 脳腫瘍治療薬市場適応症別

• 神経膠芽腫
• 髄膜腫
• 下垂体腫瘍

第8章 脳腫瘍治療薬市場：流通チャネル別

• 病院薬局
• 小売薬局

第9章 南北アメリカの脳腫瘍治療薬市場

• アルゼンチン
• ブラジル
• カナダ
• メキシコ
• 米国

第10章 アジア太平洋地域の脳腫瘍治療薬市場

• オーストラリア
• 中国
• インド
• インドネシア
• 日本
• マレーシア
• フィリピン
• シンガポール
• 韓国
• 台湾
• タイ
• ベトナム

第11章 欧州・中東・アフリカの脳腫瘍治療薬市場

• デンマーク
• エジプト
• フィンランド
• フランス
• ドイツ
• イスラエル
• イタリア
• オランダ
• ナイジェリア
• ノルウェー
• ポーランド
• カタール
• ロシア
• サウジアラビア
• 南アフリカ
• スペイン
• スウェーデン
• スイス
• トルコ
• アラブ首長国連邦
• 英国

第12章 競合情勢

• 市場シェア分析2023
• FPNVポジショニングマトリックス, 2023
• 競合シナリオ分析
• 戦略分析と提言

企業一覧

• Antisense Therapeutics Limited
• Aravive, Inc.
• AstraZeneca PLC
• Bristol Myers Squibb Company
• Dr. Reddy's Laboratories
• Elevar Therapeutics, Inc.
• F. Hoffmann-La Roche AG
• Fujifilm Corporation
• GE Healthcare
• Hitachi, Ltd.
• Johnson & Johnson Services Inc.
• Koninklijke Philips N.V.
• Leadiant Biosciences, Inc.
• Mankind Pharma Pvt. Ltd.
• Merck & Co., Inc.
• Novartis International AG
• Pfizer, Inc.
• Siemens Healthineers AG
• Thermo Fisher Scientific, Inc.

LIST OF FIGURES

• FIGURE 1. BRAIN CANCER DRUGS MARKET RESEARCH PROCESS
• FIGURE 2. BRAIN CANCER DRUGS MARKET SIZE, 2023 VS 2030
• FIGURE 3. GLOBAL BRAIN CANCER DRUGS MARKET SIZE, 2018-2030 (USD MILLION)
• FIGURE 4. GLOBAL BRAIN CANCER DRUGS MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 5. GLOBAL BRAIN CANCER DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 6. GLOBAL BRAIN CANCER DRUGS MARKET SIZE, BY THERAPY TYPE, 2023 VS 2030 (%)
• FIGURE 7. GLOBAL BRAIN CANCER DRUGS MARKET SIZE, BY THERAPY TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 8. GLOBAL BRAIN CANCER DRUGS MARKET SIZE, BY INDICATION, 2023 VS 2030 (%)
• FIGURE 9. GLOBAL BRAIN CANCER DRUGS MARKET SIZE, BY INDICATION, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 10. GLOBAL BRAIN CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2030 (%)
• FIGURE 11. GLOBAL BRAIN CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 12. AMERICAS BRAIN CANCER DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 13. AMERICAS BRAIN CANCER DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 14. UNITED STATES BRAIN CANCER DRUGS MARKET SIZE, BY STATE, 2023 VS 2030 (%)
• FIGURE 15. UNITED STATES BRAIN CANCER DRUGS MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 16. ASIA-PACIFIC BRAIN CANCER DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 17. ASIA-PACIFIC BRAIN CANCER DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 18. EUROPE, MIDDLE EAST & AFRICA BRAIN CANCER DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 19. EUROPE, MIDDLE EAST & AFRICA BRAIN CANCER DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 20. BRAIN CANCER DRUGS MARKET SHARE, BY KEY PLAYER, 2023
• FIGURE 21. BRAIN CANCER DRUGS MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

• TABLE 1. BRAIN CANCER DRUGS MARKET SEGMENTATION & COVERAGE
• TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
• TABLE 3. GLOBAL BRAIN CANCER DRUGS MARKET SIZE, 2018-2030 (USD MILLION)
• TABLE 4. GLOBAL BRAIN CANCER DRUGS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 5. GLOBAL BRAIN CANCER DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 6. BRAIN CANCER DRUGS MARKET DYNAMICS
• TABLE 7. GLOBAL BRAIN CANCER DRUGS MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
• TABLE 8. GLOBAL BRAIN CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY, BY REGION, 2018-2030 (USD MILLION)
• TABLE 9. GLOBAL BRAIN CANCER DRUGS MARKET SIZE, BY IMMUNOTHERAPY, BY REGION, 2018-2030 (USD MILLION)
• TABLE 10. GLOBAL BRAIN CANCER DRUGS MARKET SIZE, BY TARGETED THERAPY, BY REGION, 2018-2030 (USD MILLION)
• TABLE 11. GLOBAL BRAIN CANCER DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 12. GLOBAL BRAIN CANCER DRUGS MARKET SIZE, BY GLIOBLASTOMA, BY REGION, 2018-2030 (USD MILLION)
• TABLE 13. GLOBAL BRAIN CANCER DRUGS MARKET SIZE, BY MENINGIOMA, BY REGION, 2018-2030 (USD MILLION)
• TABLE 14. GLOBAL BRAIN CANCER DRUGS MARKET SIZE, BY PITUITARY TUMORS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 15. GLOBAL BRAIN CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 16. GLOBAL BRAIN CANCER DRUGS MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2018-2030 (USD MILLION)
• TABLE 17. GLOBAL BRAIN CANCER DRUGS MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2018-2030 (USD MILLION)
• TABLE 18. AMERICAS BRAIN CANCER DRUGS MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
• TABLE 19. AMERICAS BRAIN CANCER DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 20. AMERICAS BRAIN CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 21. AMERICAS BRAIN CANCER DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 22. ARGENTINA BRAIN CANCER DRUGS MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
• TABLE 23. ARGENTINA BRAIN CANCER DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 24. ARGENTINA BRAIN CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 25. BRAZIL BRAIN CANCER DRUGS MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
• TABLE 26. BRAZIL BRAIN CANCER DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 27. BRAZIL BRAIN CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 28. CANADA BRAIN CANCER DRUGS MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
• TABLE 29. CANADA BRAIN CANCER DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 30. CANADA BRAIN CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 31. MEXICO BRAIN CANCER DRUGS MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
• TABLE 32. MEXICO BRAIN CANCER DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 33. MEXICO BRAIN CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 34. UNITED STATES BRAIN CANCER DRUGS MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
• TABLE 35. UNITED STATES BRAIN CANCER DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 36. UNITED STATES BRAIN CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 37. UNITED STATES BRAIN CANCER DRUGS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
• TABLE 38. ASIA-PACIFIC BRAIN CANCER DRUGS MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
• TABLE 39. ASIA-PACIFIC BRAIN CANCER DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 40. ASIA-PACIFIC BRAIN CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 41. ASIA-PACIFIC BRAIN CANCER DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 42. AUSTRALIA BRAIN CANCER DRUGS MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
• TABLE 43. AUSTRALIA BRAIN CANCER DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 44. AUSTRALIA BRAIN CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 45. CHINA BRAIN CANCER DRUGS MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
• TABLE 46. CHINA BRAIN CANCER DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 47. CHINA BRAIN CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 48. INDIA BRAIN CANCER DRUGS MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
• TABLE 49. INDIA BRAIN CANCER DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 50. INDIA BRAIN CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 51. INDONESIA BRAIN CANCER DRUGS MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
• TABLE 52. INDONESIA BRAIN CANCER DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 53. INDONESIA BRAIN CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 54. JAPAN BRAIN CANCER DRUGS MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
• TABLE 55. JAPAN BRAIN CANCER DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 56. JAPAN BRAIN CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 57. MALAYSIA BRAIN CANCER DRUGS MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
• TABLE 58. MALAYSIA BRAIN CANCER DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 59. MALAYSIA BRAIN CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 60. PHILIPPINES BRAIN CANCER DRUGS MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
• TABLE 61. PHILIPPINES BRAIN CANCER DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 62. PHILIPPINES BRAIN CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 63. SINGAPORE BRAIN CANCER DRUGS MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
• TABLE 64. SINGAPORE BRAIN CANCER DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 65. SINGAPORE BRAIN CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 66. SOUTH KOREA BRAIN CANCER DRUGS MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
• TABLE 67. SOUTH KOREA BRAIN CANCER DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 68. SOUTH KOREA BRAIN CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 69. TAIWAN BRAIN CANCER DRUGS MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
• TABLE 70. TAIWAN BRAIN CANCER DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 71. TAIWAN BRAIN CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 72. THAILAND BRAIN CANCER DRUGS MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
• TABLE 73. THAILAND BRAIN CANCER DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 74. THAILAND BRAIN CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 75. VIETNAM BRAIN CANCER DRUGS MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
• TABLE 76. VIETNAM BRAIN CANCER DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 77. VIETNAM BRAIN CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 78. EUROPE, MIDDLE EAST & AFRICA BRAIN CANCER DRUGS MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
• TABLE 79. EUROPE, MIDDLE EAST & AFRICA BRAIN CANCER DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 80. EUROPE, MIDDLE EAST & AFRICA BRAIN CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 81. EUROPE, MIDDLE EAST & AFRICA BRAIN CANCER DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 82. DENMARK BRAIN CANCER DRUGS MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
• TABLE 83. DENMARK BRAIN CANCER DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 84. DENMARK BRAIN CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 85. EGYPT BRAIN CANCER DRUGS MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
• TABLE 86. EGYPT BRAIN CANCER DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 87. EGYPT BRAIN CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 88. FINLAND BRAIN CANCER DRUGS MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
• TABLE 89. FINLAND BRAIN CANCER DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 90. FINLAND BRAIN CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 91. FRANCE BRAIN CANCER DRUGS MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
• TABLE 92. FRANCE BRAIN CANCER DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 93. FRANCE BRAIN CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 94. GERMANY BRAIN CANCER DRUGS MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
• TABLE 95. GERMANY BRAIN CANCER DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 96. GERMANY BRAIN CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 97. ISRAEL BRAIN CANCER DRUGS MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
• TABLE 98. ISRAEL BRAIN CANCER DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 99. ISRAEL BRAIN CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 100. ITALY BRAIN CANCER DRUGS MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
• TABLE 101. ITALY BRAIN CANCER DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 102. ITALY BRAIN CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 103. NETHERLANDS BRAIN CANCER DRUGS MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
• TABLE 104. NETHERLANDS BRAIN CANCER DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 105. NETHERLANDS BRAIN CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 106. NIGERIA BRAIN CANCER DRUGS MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
• TABLE 107. NIGERIA BRAIN CANCER DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 108. NIGERIA BRAIN CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 109. NORWAY BRAIN CANCER DRUGS MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
• TABLE 110. NORWAY BRAIN CANCER DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 111. NORWAY BRAIN CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 112. POLAND BRAIN CANCER DRUGS MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
• TABLE 113. POLAND BRAIN CANCER DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 114. POLAND BRAIN CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 115. QATAR BRAIN CANCER DRUGS MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
• TABLE 116. QATAR BRAIN CANCER DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 117. QATAR BRAIN CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 118. RUSSIA BRAIN CANCER DRUGS MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
• TABLE 119. RUSSIA BRAIN CANCER DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 120. RUSSIA BRAIN CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 121. SAUDI ARABIA BRAIN CANCER DRUGS MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
• TABLE 122. SAUDI ARABIA BRAIN CANCER DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 123. SAUDI ARABIA BRAIN CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 124. SOUTH AFRICA BRAIN CANCER DRUGS MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
• TABLE 125. SOUTH AFRICA BRAIN CANCER DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 126. SOUTH AFRICA BRAIN CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 127. SPAIN BRAIN CANCER DRUGS MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
• TABLE 128. SPAIN BRAIN CANCER DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 129. SPAIN BRAIN CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 130. SWEDEN BRAIN CANCER DRUGS MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
• TABLE 131. SWEDEN BRAIN CANCER DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 132. SWEDEN BRAIN CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 133. SWITZERLAND BRAIN CANCER DRUGS MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
• TABLE 134. SWITZERLAND BRAIN CANCER DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 135. SWITZERLAND BRAIN CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 136. TURKEY BRAIN CANCER DRUGS MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
• TABLE 137. TURKEY BRAIN CANCER DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 138. TURKEY BRAIN CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 139. UNITED ARAB EMIRATES BRAIN CANCER DRUGS MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
• TABLE 140. UNITED ARAB EMIRATES BRAIN CANCER DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 141. UNITED ARAB EMIRATES BRAIN CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 142. UNITED KINGDOM BRAIN CANCER DRUGS MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
• TABLE 143. UNITED KINGDOM BRAIN CANCER DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 144. UNITED KINGDOM BRAIN CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 145. BRAIN CANCER DRUGS MARKET SHARE, BY KEY PLAYER, 2023
• TABLE 146. BRAIN CANCER DRUGS MARKET, FPNV POSITIONING MATRIX, 2023

The Brain Cancer Drugs Market was valued at USD 2.03 billion in 2023, expected to reach USD 2.18 billion in 2024, and is projected to grow at a CAGR of 7.43%, to USD 3.35 billion by 2030.

The scope of the market for brain cancer drugs encompasses the development, production, and distribution of therapeutic agents specifically targeting brain tumors. These include chemotherapy, targeted therapies, immunotherapy, and supportive care drugs aimed at treating different types of brain cancers like glioblastomas, astrocytomas, and oligodendrogliomas. The necessity for such drugs is driven by the increasing incidence of brain cancer, which requires innovative treatments that can penetrate the blood-brain barrier and offer improved efficacy with fewer side effects. The application of these drugs is mainly in hospitals, clinics, and specialized cancer treatment centers, with end-users consisting of medical professionals and patients requiring tailored cancer treatment plans.

Market growth is influenced by key factors such as advancements in medical technology, increased research funding, and rising awareness of early cancer detection. The emergence of personalized medicine and next-generation sequencing technologies provide significant opportunities for developing targeted therapies, offering growth potential. Currently, collaborations between pharmaceutical companies and research institutions are opening doors for innovative drug discovery and clinical trials. A major recommendation to capitalize on these opportunities includes investing in R&D for drugs focusing on the genetic and molecular profiling of tumors, which can enable more precise targeting and improved patient outcomes.

However, the market also faces limitations from high developmental and approval costs, stringent regulatory requirements, and challenges in effectively crossing the blood-brain barrier. Another significant challenge is the aggressive nature of some brain tumors, which often leads to high relapse rates and resistance to conventional therapies. Areas ripe for innovation include the development of drugs that can effectively target tumor vasculature and microenvironment, and novel delivery systems such as nanoparticles to enhance drug delivery to the brain. The market's nature is highly dynamic and competitive, necessitating continuous innovation and adaptation by stakeholders to meet unmet patient needs and overcome existing market constraints.

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Brain Cancer Drugs Market

The Brain Cancer Drugs Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

• Market Drivers
  • Increasing prevalence of brain cancer with sedentary lifestyles
  • Surge in geriatric population suffering from neurological disorders
  • Rising patient awareness on the availability of treatment
• Market Restraints
  • Use of targeted therapies to block cancer growth
• Market Opportunities
  • Favorable initiatives from government and pharmaceutical companies in the development of the drug
  • Robust development in areas such as use of nanoparticles to carry drugs
• Market Challenges
  • Strict regulatory guidelines in the approval of these drugs

Porter's Five Forces: A Strategic Tool for Navigating the Brain Cancer Drugs Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Brain Cancer Drugs Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Brain Cancer Drugs Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Brain Cancer Drugs Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Brain Cancer Drugs Market

A detailed market share analysis in the Brain Cancer Drugs Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Brain Cancer Drugs Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Brain Cancer Drugs Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Brain Cancer Drugs Market

A strategic analysis of the Brain Cancer Drugs Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Brain Cancer Drugs Market, highlighting leading vendors and their innovative profiles. These include Antisense Therapeutics Limited, Aravive, Inc., AstraZeneca PLC, Bristol Myers Squibb Company, Dr. Reddy's Laboratories, Elevar Therapeutics, Inc., F. Hoffmann-La Roche AG, Fujifilm Corporation, GE Healthcare, Hitachi, Ltd., Johnson & Johnson Services Inc., Koninklijke Philips N.V., Leadiant Biosciences, Inc., Mankind Pharma Pvt. Ltd., Merck & Co., Inc., Novartis International AG, Pfizer, Inc., Siemens Healthineers AG, and Thermo Fisher Scientific, Inc..

Market Segmentation & Coverage

This research report categorizes the Brain Cancer Drugs Market to forecast the revenues and analyze trends in each of the following sub-markets:

• Based on Therapy Type, market is studied across Chemotherapy, Immunotherapy, and Targeted Therapy.
• Based on Indication, market is studied across Glioblastoma, Meningioma, and Pituitary Tumors.
• Based on Distribution Channel, market is studied across Hospital Pharmacy and Retail pharmacy.
• Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Segmentation & Coverage
• 1.3. Years Considered for the Study
• 1.4. Currency & Pricing
• 1.5. Language
• 1.6. Stakeholders

2. Research Methodology

• 2.1. Define: Research Objective
• 2.2. Determine: Research Design
• 2.3. Prepare: Research Instrument
• 2.4. Collect: Data Source
• 2.5. Analyze: Data Interpretation
• 2.6. Formulate: Data Verification
• 2.7. Publish: Research Report
• 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

• 5.1. Market Dynamics
  • 5.1.1. Drivers
    • 5.1.1.1. Increasing prevalence of brain cancer with sedentary lifestyles
    • 5.1.1.2. Surge in geriatric population suffering from neurological disorders
    • 5.1.1.3. Rising patient awareness on the availability of treatment
  • 5.1.2. Restraints
    • 5.1.2.1. Use of targeted therapies to block cancer growth
  • 5.1.3. Opportunities
    • 5.1.3.1. Favorable initiatives from government and pharmaceutical companies in the development of the drug
    • 5.1.3.2. Robust development in areas such as use of nanoparticles to carry drugs
  • 5.1.4. Challenges
    • 5.1.4.1. Strict regulatory guidelines in the approval of these drugs
• 5.2. Market Segmentation Analysis
• 5.3. Porter's Five Forces Analysis
  • 5.3.1. Threat of New Entrants
  • 5.3.2. Threat of Substitutes
  • 5.3.3. Bargaining Power of Customers
  • 5.3.4. Bargaining Power of Suppliers
  • 5.3.5. Industry Rivalry
• 5.4. PESTLE Analysis
  • 5.4.1. Political
  • 5.4.2. Economic
  • 5.4.3. Social
  • 5.4.4. Technological
  • 5.4.5. Legal
  • 5.4.6. Environmental

6. Brain Cancer Drugs Market, by Therapy Type

• 6.1. Introduction
• 6.2. Chemotherapy
• 6.3. Immunotherapy
• 6.4. Targeted Therapy

7. Brain Cancer Drugs Market, by Indication

• 7.1. Introduction
• 7.2. Glioblastoma
• 7.3. Meningioma
• 7.4. Pituitary Tumors

8. Brain Cancer Drugs Market, by Distribution Channel

• 8.1. Introduction
• 8.2. Hospital Pharmacy
• 8.3. Retail pharmacy

9. Americas Brain Cancer Drugs Market

• 9.1. Introduction
• 9.2. Argentina
• 9.3. Brazil
• 9.4. Canada
• 9.5. Mexico
• 9.6. United States

10. Asia-Pacific Brain Cancer Drugs Market

• 10.1. Introduction
• 10.2. Australia
• 10.3. China
• 10.4. India
• 10.5. Indonesia
• 10.6. Japan
• 10.7. Malaysia
• 10.8. Philippines
• 10.9. Singapore
• 10.10. South Korea
• 10.11. Taiwan
• 10.12. Thailand
• 10.13. Vietnam

11. Europe, Middle East & Africa Brain Cancer Drugs Market

• 11.1. Introduction
• 11.2. Denmark
• 11.3. Egypt
• 11.4. Finland
• 11.5. France
• 11.6. Germany
• 11.7. Israel
• 11.8. Italy
• 11.9. Netherlands
• 11.10. Nigeria
• 11.11. Norway
• 11.12. Poland
• 11.13. Qatar
• 11.14. Russia
• 11.15. Saudi Arabia
• 11.16. South Africa
• 11.17. Spain
• 11.18. Sweden
• 11.19. Switzerland
• 11.20. Turkey
• 11.21. United Arab Emirates
• 11.22. United Kingdom

12. Competitive Landscape

• 12.1. Market Share Analysis, 2023
• 12.2. FPNV Positioning Matrix, 2023
• 12.3. Competitive Scenario Analysis
• 12.4. Strategy Analysis & Recommendation

Companies Mentioned

• 1. Antisense Therapeutics Limited
• 2. Aravive, Inc.
• 3. AstraZeneca PLC
• 4. Bristol Myers Squibb Company
• 5. Dr. Reddy's Laboratories
• 6. Elevar Therapeutics, Inc.
• 7. F. Hoffmann-La Roche AG
• 8. Fujifilm Corporation
• 9. GE Healthcare
• 10. Hitachi, Ltd.
• 11. Johnson & Johnson Services Inc.
• 12. Koninklijke Philips N.V.
• 13. Leadiant Biosciences, Inc.
• 14. Mankind Pharma Pvt. Ltd.
• 15. Merck & Co., Inc.
• 16. Novartis International AG
• 17. Pfizer, Inc.
• 18. Siemens Healthineers AG
• 19. Thermo Fisher Scientific, Inc.